850073-72-2

Basic information

• Product Name: 6-methoxycarbonylbenzothiophene-2-carboxylic acid
• Synonyms: 6-(methoxycarbonyl)-1-benzothiophene-2-carboxylic acid
• CAS NO: 850073-72-2
• Molecular Formula: C₁₁H₈O₄S
• Molecular Weight: 236.24
• Mol File: 850073-72-2.mol

Chemical Properties

• Boiling Point: 437.5°C at 760 mmHg
• Flash Point: 218.4°C
• Density: 1.445g/cm³
• Vapor Pressure: 1.99E-08mmHg at 25°C
• Refractive Index: 1.671
• CAS DataBase Reference: 6-methoxycarbonylbenzothiophene-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methoxycarbonylbenzothiophene-2-carboxylic acid(850073-72-2)
• EPA Substance Registry System: 6-methoxycarbonylbenzothiophene-2-carboxylic acid(850073-72-2)

Safety Data

• Hazardous Substances Data: 850073-72-2(Hazardous Substances Data)

Upstream product

• 850074-42-9 2-ethyl 6-methyl benzo[b]thiophene-2,6-dicarboxylate 
• 850073-71-1 dimethyl benzo[b]thiophene-2,6-dicarboxylate 
• 153813-69-5 methyl 4-formyl-3-nitrobenzoate 

Downstream Products

• 850073-74-4 2-trityloxycarbamoyl-benzo[b]thiophene-6-carboxylic acid methyl ester 
• 850073-75-5 2-trityloxycarbamoyl-benzo[b]thiophene-6-carboxylic acid 

Relevant articles and documents

Benzocarbazoles five-membered unsaturated heterocyclic compound or its pharmaceutically acceptable salts and its preparation method, pharmaceutical composition and its application

Provided in the present invention are an unsaturated 5-membered benzo-heterocyclic compound with the structure as shown in general formula I or pharmaceutical salts thereof, and a preparation method, a pharmaceutical composition and the use thereof. Experiments have shown that the compound of the present invention has the effects of upregulating the expression activity of bone morphogenetic protein BMP-2 and anti-osteoporosis in vivo, and also has the effect of improving SAMP6 mice osteoporosis symptoms. Activity tests in vitro have shown that the compound of the present invention shows an obvious upregulation effect on bone morphogenetic protein BMP-2.

Benzo[b]thiophene-based histone deacetylase inhibitors

Benzo[b]thienyl hydroxamic acids, a novel class of histone deacetylase (HDAC) inhibitors, were identified via a targeted screen of small molecule hydroxamic acids. Various substitutions were explored in the C5- and C6-positions of the benzo[b]thiophene co

BENZOTHIOPHENE DERIVATIVES

The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES

The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and